Quantum computing Market Growth and Status Explored in a New Research Report 2035
Drug discovery has always been a time-consuming process. On an average, it takes 10-15 years and capital investments worth USD 4-10 billion to commercially launch a drug.
The global quantum computing market size is estimated to grow from USD 0.39 billion in 2024 to USD 1.63 billion by 2035, representing a CAGR of 13.86% during the forecast period till 2035.
Company Competitiveness of Quantum Computing Software Providers
In this analysis, we have presented a detailed competitiveness analysis of the quantum computing software providers based in North America, Europe, Asia-Pacific and Rest of the World. The companies considered in this analysis have been scored on various relevant parameters, such as company strength (in terms of number of years since it was established), portfolio strength (this parameter evaluates a company’s portfolio strength based on the type of drug discovery service(s) offered, types of molecule(s) support, compatible computational approaches and end user(s)), portfolio diversity (this parameter evaluates a company’s portfolio diversity based on the type of business capabilities). The primary purpose of this analysis was to develop a better understanding of the overall potential and capabilities of companies involved in this domain. In addition, it provides a reliable framework for geographical benchmarking of the capabilities of industry stakeholders.
Read More :- https://www.rootsanalysis.com/reports/quantum-computing-in-drug-discovery.html
Drug discovery has always been a time-consuming process. On an average, it takes 10-15 years and capital investments worth USD 4-10 billion to commercially launch a drug.
The global quantum computing market size is estimated to grow from USD 0.39 billion in 2024 to USD 1.63 billion by 2035, representing a CAGR of 13.86% during the forecast period till 2035.
Company Competitiveness of Quantum Computing Software Providers
In this analysis, we have presented a detailed competitiveness analysis of the quantum computing software providers based in North America, Europe, Asia-Pacific and Rest of the World. The companies considered in this analysis have been scored on various relevant parameters, such as company strength (in terms of number of years since it was established), portfolio strength (this parameter evaluates a company’s portfolio strength based on the type of drug discovery service(s) offered, types of molecule(s) support, compatible computational approaches and end user(s)), portfolio diversity (this parameter evaluates a company’s portfolio diversity based on the type of business capabilities). The primary purpose of this analysis was to develop a better understanding of the overall potential and capabilities of companies involved in this domain. In addition, it provides a reliable framework for geographical benchmarking of the capabilities of industry stakeholders.
Read More :- https://www.rootsanalysis.com/reports/quantum-computing-in-drug-discovery.html
Quantum computing Market Growth and Status Explored in a New Research Report 2035
Drug discovery has always been a time-consuming process. On an average, it takes 10-15 years and capital investments worth USD 4-10 billion to commercially launch a drug.
The global quantum computing market size is estimated to grow from USD 0.39 billion in 2024 to USD 1.63 billion by 2035, representing a CAGR of 13.86% during the forecast period till 2035.
Company Competitiveness of Quantum Computing Software Providers
In this analysis, we have presented a detailed competitiveness analysis of the quantum computing software providers based in North America, Europe, Asia-Pacific and Rest of the World. The companies considered in this analysis have been scored on various relevant parameters, such as company strength (in terms of number of years since it was established), portfolio strength (this parameter evaluates a company’s portfolio strength based on the type of drug discovery service(s) offered, types of molecule(s) support, compatible computational approaches and end user(s)), portfolio diversity (this parameter evaluates a company’s portfolio diversity based on the type of business capabilities). The primary purpose of this analysis was to develop a better understanding of the overall potential and capabilities of companies involved in this domain. In addition, it provides a reliable framework for geographical benchmarking of the capabilities of industry stakeholders.
Read More :- https://www.rootsanalysis.com/reports/quantum-computing-in-drug-discovery.html
0 Comments
0 Shares
140 Views
0 Reviews